Anil Shanker to Humans
This is a "connection" page, showing publications Anil Shanker has written about Humans.
Connection Strength
0.687
-
Uzhachenko R, Shimamoto A, Chirwa SS, Ivanov SV, Ivanova AV, Shanker A. Mitochondrial Fus1/Tusc2 and cellular Ca2+ homeostasis: tumor suppressor, anti-inflammatory and anti-aging implications. Cancer Gene Ther. 2022 10; 29(10):1307-1320.
Score: 0.041
-
Renrick AN, Thounaojam MC, de Aquino MTP, Chaudhuri E, Pandhare J, Dash C, Shanker A. Bortezomib Sustains T Cell Function by Inducing miR-155-Mediated Downregulation of SOCS1 and SHIP1. Front Immunol. 2021; 12:607044.
Score: 0.038
-
Hodo TW, de Aquino MTP, Shimamoto A, Shanker A. Critical Neurotransmitters in the Neuroimmune Network. Front Immunol. 2020; 11:1869.
Score: 0.037
-
Srivastava RM, Marincola FM, Shanker A. Editorial: Lymphocyte Functional Crosstalk and Regulation. Front Immunol. 2019; 10:2916.
Score: 0.035
-
Uzhachenko RV, Shanker A. CD8+ T Lymphocyte and NK Cell Network: Circuitry in the Cytotoxic Domain of Immunity. Front Immunol. 2019; 10:1906.
Score: 0.034
-
Renrick AN, Dunbar ZT, Shanker A. Update?on the current revolution in cancer immunotherapy. Immunotherapy. 2019 01; 11(1):15-20.
Score: 0.033
-
Shanker A, Thounaojam MC, Mishra MK, Dikov MM. Innate-Adaptive Immune Crosstalk 2016. J Immunol Res. 2017; 2017:3503207.
Score: 0.029
-
Pellom ST, Singhal A, Shanker A. Prospects of combining adoptive cell immunotherapy with bortezomib. Immunotherapy. 2017 03; 9(4):305-308.
Score: 0.029
-
Pulliam SR, Uzhachenko RV, Adunyah SE, Shanker A. Common gamma chain cytokines in combinatorial immune strategies against cancer. Immunol Lett. 2016 Jan; 169:61-72.
Score: 0.027
-
Shanker A, Thounaojam MC, Mishra MK, Dikov MM, Uzhachenko RV. Innate-Adaptive Immune Crosstalk. J Immunol Res. 2015; 2015:982465.
Score: 0.027
-
Shanker A, Pellom ST, Dudimah DF, Thounaojam MC, de Kluyver RL, Brooks AD, Yagita H, McVicar DW, Murphy WJ, Longo DL, Sayers TJ. Bortezomib Improves Adoptive T-cell Therapy by Sensitizing Cancer Cells to FasL Cytotoxicity. Cancer Res. 2015 Dec 15; 75(24):5260-72.
Score: 0.026
-
Thounaojam MC, Dudimah DF, Pellom ST, Uzhachenko RV, Carbone DP, Dikov MM, Shanker A. Bortezomib enhances expression of effector molecules in anti-tumor CD8+ T lymphocytes by promoting Notch-nuclear factor-?B crosstalk. Oncotarget. 2015 Oct 20; 6(32):32439-55.
Score: 0.026
-
Shanker A, Dikov MM, Carbone DP. Promise of Immunotherapy in Lung Cancer. Prog Tumor Res. 2015; 42:95-109.
Score: 0.026
-
Pellom ST, Dudimah DF, Thounaojam MC, Sayers TJ, Shanker A. Modulatory effects of bortezomib on host immune cell functions. Immunotherapy. 2015; 7(9):1011-22.
Score: 0.026
-
de Aquino MT, Malhotra A, Mishra MK, Shanker A. Challenges and future perspectives of T cell immunotherapy in cancer. Immunol Lett. 2015 Aug; 166(2):117-33.
Score: 0.026
-
Malhotra A, Shanker A. NK cells: immune cross-talk and therapeutic implications. Immunotherapy. 2011 Oct; 3(10):1143-66.
Score: 0.020
-
Shanker A, Marincola FM. Cooperativity of adaptive and innate immunity: implications for cancer therapy. Cancer Immunol Immunother. 2011 Aug; 60(8):1061-74.
Score: 0.020
-
Shanker A. Adaptive control of innate immunity. Immunol Lett. 2010 Jul 08; 131(2):107-12.
Score: 0.018
-
Shanker A, Brooks AD, Tristan CA, Wine JW, Elliott PJ, Yagita H, Takeda K, Smyth MJ, Murphy WJ, Sayers TJ. Treating metastatic solid tumors with bortezomib and a tumor necrosis factor-related apoptosis-inducing ligand receptor agonist antibody. J Natl Cancer Inst. 2008 May 07; 100(9):649-62.
Score: 0.016
-
Shanker A, Sayers T. Sensitizing tumor cells to immune-mediated cytotoxicity. Adv Exp Med Biol. 2007; 601:163-71.
Score: 0.014
-
Shanker A. Is thymus redundant after adulthood? Immunol Lett. 2004 Feb 15; 91(2-3):79-86.
Score: 0.012
-
Evans JV, Suman S, Goruganthu MUL, Tchekneva EE, Guan S, Arasada RR, Antonucci A, Piao L, Ilgisonis I, Bobko AA, Driesschaert B, Uzhachenko RV, Hoyd R, Samouilov A, Amann J, Wu R, Wei L, Pallerla A, Ryzhov SV, Feoktistov I, Park KP, Kikuchi T, Castro J, Ivanova AV, Kanagasabai T, Owen DH, Spakowicz DJ, Zweier JL, Carbone DP, Novitskiy SV, Khramtsov VV, Shanker A, Dikov MM. Improving combination therapies: targeting A2B-adenosine receptor to modulate metabolic tumor microenvironment and immunosuppression. J Natl Cancer Inst. 2023 11 08; 115(11):1404-1419.
Score: 0.012
-
Tewary P, Brooks AD, Xu YM, Wijeratne EMK, Babyak AL, Back TC, Chari R, Evans CN, Henrich CJ, Meyer TJ, Edmondson EF, de Aquino MTP, Kanagasabai T, Shanker A, Gunatilaka AAL, Sayers TJ. Small-Molecule Natural Product Physachenolide C Potentiates Immunotherapy Efficacy by Targeting BET Proteins. Cancer Res. 2021 06 15; 81(12):3374-3386.
Score: 0.010
-
Rana T, Korolkova OY, Rachakonda G, Williams AD, Hawkins AT, James SD, Sakwe AM, Hui N, Wang L, Yu C, Goodwin JS, Izban MG, Offodile RS, Washington MK, Ballard BR, Smoot DT, Shi XZ, Forbes DS, Shanker A, M'Koma AE. Linking bacterial enterotoxins and alpha defensin 5 expansion in the Crohn's colitis: A new insight into the etiopathogenetic and differentiation triggers driving colonic inflammatory bowel disease. PLoS One. 2021; 16(3):e0246393.
Score: 0.010
-
Thomas PL, Nangami G, Rana T, Evans A, Williams SD, Crowell D, Shanker A, Sakwe AM, Ochieng J. The rapid endocytic uptake of fetuin-A by adherent tumor cells is mediated by Toll-like receptor 4 (TLR4). FEBS Open Bio. 2020 12; 10(12):2722-2732.
Score: 0.009
-
Goruganthu MUL, Shanker A, Dikov MM, Carbone DP. Specific Targeting of Notch Ligand-Receptor Interactions to Modulate Immune Responses: A Review of Clinical and Preclinical Findings. Front Immunol. 2020; 11:1958.
Score: 0.009
-
Patel JD, Lee JW, Carbone DP, Wagner H, Shanker A, de Aquino MTP, Horn L, Johnson ML, Gerber DE, Liu JJ, Das MS, Al-Nsour MA, Dakhil CSR, Ramalingam S, Schiller JH. Phase II Study of Immunotherapy With Tecemotide and Bevacizumab After Chemoradiation in Patients With Unresectable Stage III Non-Squamous Non-Small-Cell Lung?Cancer (NS-NSCLC): A Trial of the ECOG-ACRIN Cancer Research Group (E6508). Clin Lung Cancer. 2020 11; 21(6):520-526.
Score: 0.009
-
Tchekneva EE, Goruganthu MUL, Uzhachenko RV, Thomas PL, Antonucci A, Chekneva I, Koenig M, Piao L, Akhter A, de Aquino MTP, Ranganathan P, Long N, Magliery T, Valujskikh A, Evans JV, Arasada RR, Massion PP, Carbone DP, Shanker A, Dikov MM. Determinant roles of dendritic cell-expressed Notch Delta-like and Jagged ligands on anti-tumor T?cell immunity. J Immunother Cancer. 2019 04 02; 7(1):95.
Score: 0.008
-
Uzhachenko R, Shanker A, Dupont G. Computational properties of mitochondria in T cell activation and fate. Open Biol. 2016 11; 6(11).
Score: 0.007
-
Lawrence S, Pellom ST, Shanker A, Whalen MM. Tributyltin exposure alters cytokine levels in mouse serum. J Immunotoxicol. 2016 11; 13(6):870-878.
Score: 0.007
-
Pulliam SR, Pellom ST, Shanker A, Adunyah SE. Butyrate regulates the expression of inflammatory and chemotactic cytokines in human acute leukemic cells during apoptosis. Cytokine. 2016 08; 84:74-87.
Score: 0.007
-
Clark RS, Pellom ST, Booker B, Ramesh A, Zhang T, Shanker A, Maguire M, Juarez PD, Patricia MJ, Langston MA, Lichtveld MY, Hood DB. Validation of research trajectory 1 of an Exposome framework: Exposure to benzo(a)pyrene confers enhanced susceptibility to bacterial infection. Environ Res. 2016 Apr; 146:173-84.
Score: 0.007
-
Biktasova AK, Dudimah DF, Uzhachenko RV, Park K, Akhter A, Arasada RR, Evans JV, Novitskiy SV, Tchekneva EE, Carbone DP, Shanker A, Dikov MM. Multivalent Forms of the Notch Ligand DLL-1 Enhance Antitumor T-cell Immunity in Lung Cancer and Improve Efficacy of EGFR-Targeted Therapy. Cancer Res. 2015 Nov 15; 75(22):4728-41.
Score: 0.007
-
Uzhachenko R, Shanker A, Yarbrough WG, Ivanova AV. Mitochondria, calcium, and tumor suppressor Fus1: At the crossroad of cancer, inflammation, and autoimmunity. Oncotarget. 2015 Aug 28; 6(25):20754-72.
Score: 0.007
-
Ascierto ML, Idowu MO, Zhao Y, Khalak H, Payne KK, Wang XY, Dumur CI, Bedognetti D, Tomei S, Ascierto PA, Shanker A, Bear HD, Wang E, Marincola FM, De Maria A, Manjili MH. Molecular signatures mostly associated with NK cells are predictive of relapse free survival in breast cancer patients. J Transl Med. 2013 Jun 12; 11:145.
Score: 0.006
-
Huang Y, Lin L, Shanker A, Malhotra A, Yang L, Dikov MM, Carbone DP. Resuscitating cancer immunosurveillance: selective stimulation of DLL1-Notch signaling in T cells rescues T-cell function and inhibits tumor growth. Cancer Res. 2011 Oct 01; 71(19):6122-31.
Score: 0.005
-
Brooks AD, Jacobsen KM, Li W, Shanker A, Sayers TJ. Bortezomib sensitizes human renal cell carcinomas to TRAIL apoptosis through increased activation of caspase-8 in the death-inducing signaling complex. Mol Cancer Res. 2010 May; 8(5):729-38.
Score: 0.005
-
Cretney E, Shanker A, Yagita H, Smyth MJ, Sayers TJ. TNF-related apoptosis-inducing ligand as a therapeutic agent in autoimmunity and cancer. Immunol Cell Biol. 2006 Feb; 84(1):87-98.
Score: 0.003